WELL’s Strategic U.S. Exit Creates Alpha in Canadian Core Reset

The core expectation gap here is stark. The market was braced for a strong report, and WELL delivered a record profitability beat. Yet the stock fell. This is the classic "sell the news" dynamic in action, where the reality of the print clashes with the whisper number and the forward view.

The numbers themselves are impressive. For the fourth quarter, adjusted earnings per share came in at CAD 0.20, crushing the consensus estimate of CAD 0.1035-a 93% beat. Adjusted EBITDA also topped expectations at CAD 66.5 million versus an estimate of CAD 63 million. On a full-year basis, the story is transformational: adjusted EBITDA surged 336% to CAD 203.7 million in 2025, a figure that includes the massive contribution from its U.S. care businesses.

Yet the setup for disappointment was already priced in. The revenue print was a slight miss. Q4 revenue of CAD 384.8 million fell just shy of the CAD 386 million consensus. More critically, the guidance reset for 2026 was a clear downgrade from the implied trajectory. The company is now guiding for 2026 revenue of CAD 1.55 to 1.65 billion and adjusted EBITDA of CAD 175 to 185 million. That EBITDA range is notably lower than the estimated CAD 207.5 million implied by the 2025 run-rate, signaling a strategic reset.

The market's reaction makes perfect sense when viewed through this lens. The beat on earnings was overshadowed by the revenue miss and, more importantly, the guidance that acknowledges the loss of high-margin U.S. assets. Investors were looking for a beat-and-raise narrative to justify a higher multiple, but got a beat-and-a-lower-forward view. The expectation gap wasn't in the quarterly results themselves, but in the path forward. The stock's decline reflects a reassessment of the growth story, moving from a hyper-growth, asset-heavy model to a more moderate, normalized Canadian-focused trajectory.

The Strategic Reset: What's Being Sold and Why

The market's reaction to the earnings beat was a direct response to a fundamental shift in the company's growth model. WELL is actively selling its high-flying U.S. portfolio, and that pivot is now the core of its forward story. The company has an agreement in principle with the DOJ on Circle-related matters and is actively seeking buyers for its U.S. assets, including Circle Medical and CRH. This isn't a minor divestiture; it's a strategic repositioning away from the hyper-growth, asset-heavy U.S. model that powered the 2025 results.

The math behind the reset is clear. The reported 2025 adjusted EBITDA of CAD 203.7 million includes the massive contribution from these U.S. businesses. On a normalized basis, excluding the impact of Circle Medical's deferred revenue and one-time items at CRH, the story is more disciplined. Normalized adjusted EBITDA grew just 17% to CAD 148.6 million. That's the underlying engine the company now wants to build on.

The new target is a slower, more predictable pace. Management has stated its capital allocation strategy is aimed at ensuring at least 10% growth in normalized adjusted EBITDA annually. This is a significant step down from the 336% surge in reported EBITDA and the 17% normalized growth. It signals a move from explosive, acquisition-driven expansion to a focus on organic growth and disciplined M&A within its Canadian core.

Viewed another way, the company is trading a high-margin, high-risk U.S. portfolio for a more stable, lower-growth Canadian footprint. The guidance reflects this: the 2026 EBITDA range of CAD 175-185 million is notably lower than the CAD 207.5 million implied by the 2025 run-rate. The market is pricing in this reset. The expectation gap has shifted from "How much will they grow?" to "How much will they be worth after the sale?" The stock's decline after the beat shows investors are weighing the immediate profit against the long-term, lower-growth trajectory now on offer.

Valuation and the Path to Profitability

The valuation tells the real story here. With a trailing P/E ratio of -92.3, WELL is still a classic growth stock, betting that future profits will justify today's price. That negative multiple reflects its past losses and the market's focus on its path to sustained profitability. The record 2025 results-adjusted EBITDA of $203.7 million and a reported margin of 14.5%-show the company is finally crossing that threshold. But the normalized picture is more telling. On a normalized basis, excluding one-time U.S. impacts, the company's adjusted EBITDA grew just 17% to $148.6 million. That's the underlying engine, and it's the one the market now expects to drive the new, slower growth trajectory.

Management's plan to support margin expansion is clear. The focus is on higher-margin Canadian clinic acquisitions and diagnostics. The company has a pipeline of roughly CAD 260 million in clinic revenue under LOI and is targeting assets that can lift its overall margin profile. This is a disciplined pivot from the high-margin, high-risk U.S. model it is now selling. The goal is to ensure at least 10% growth in normalized adjusted EBITDA annually through this disciplined M&A and organic growth.

Yet the execution risk is high. The expectation gap now hinges on whether this pipeline can be converted into promised results. The company's 2026 guidance implies a moderation, with adjusted EBITDA targeted between CAD 175 million and CAD 185 million. That range is notably lower than the estimated CAD 207.5 million implied by the 2025 run-rate, signaling the market is pricing in the loss of U.S. contributions. The stock's post-earnings decline shows investors are skeptical about the speed and quality of the transition. They are weighing the immediate profit against the long-term, lower-growth path. The valuation remains high for a company with a negative P/E, but the market is demanding proof that the normalized engine can deliver on its new, more modest promise.

Catalysts and Risks: What to Watch Next

The expectation gap is now a waiting game. The market has reset its view, but the real test is whether the company can execute its new, slower-growth model. The near-term catalysts are clear: progress on the U.S. asset sales and the DOJ resolution will determine the timing and value of capital returned to shareholders. This is the primary event that could narrow the gap between today's depressed valuation and the intrinsic value of the remaining Canadian core.

Simultaneously, investors must watch quarterly normalized EBITDA growth to see if the company can meet its stated target of at least 10% annual growth. The first few quarters of 2026 will be critical. A consistent beat on this normalized metric would validate the pivot to a more disciplined, higher-margin Canadian model. A miss, however, would confirm the market's skepticism and likely pressure the stock further.

The key risk lies in execution on the promised pipeline. The company has a pipeline of roughly CAD 260 million in clinic revenue under LOI and is targeting assets that can lift its margin profile. The performance of these acquisitions is the linchpin. If they fail to integrate smoothly or deliver the expected margin expansion, the entire narrative of a higher-quality, slower-growth business falls apart.

In other words, the market is now pricing in a reset. The catalysts ahead will determine if that reset is too harsh or if a new opportunity exists. Watch for sales progress, normalized growth, and pipeline execution. These are the metrics that will decide whether the current valuation gap is justified or if the expectation arbitrage is just beginning.